Statement of Advice

diclofenac 4% spray gel (Mobigel Spray ®) (No: 667/10)  
Goldshield Group Plc

05 November 2010

**ADVICE**: in the absence of a submission from the holder of the marketing authorisation
diclofenac 4% spray gel (Mobigel Spray ®): is not recommended for use within NHS Scotland.

**Indication under review**: for the local symptomatic relief of mild to moderate pain and inflammation following acute blunt trauma of small and medium-sized joints and periarticular structures.

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.

**Advice context**:  
No part of this advice may be used without the whole of the advice being quoted in full.

This advice represents the view of the Scottish Medicines Consortium. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

Chairman,  
Scottish Medicines Consortium

Published 13 December 2010